Keep in mind again in February, after we have been apprehensive a couple of market correction? Again when the NASDAQ dipped 10% from its peak… Yeah, nicely, by no means thoughts about that. Markets are up, up, up currently. A robust jobs report final Friday has helped, displaying 916,000 new positions in March, the most effective print since final August, and nearly a quarter-million greater than expectations. Rising markets make it a great time to take a look at the ‘prime picks’ from Wall Road’s inventory analysts. The three shares we’re taking a look at are an attention-grabbing lot, and so they have sure commonalities: a Sturdy Purchase consensus score, tangible upside potential for buyers, and a ‘Prime Decide’ evaluation. Utilizing the TipRanks database, we’ve pulled the main points on these shares to search out out what makes them so compelling. Listed here are the outcomes. Ascendis Pharma (ASND) First up, Ascendis Pharma, is an ‘rising’ biotechnology firm with a main concentrate on uncommon illnesses in endocrinology. The corporate has an energetic pipeline, with three drug candidates in medical trials for endocrine illnesses, together with pediatric and grownup development hormone deficiency, grownup hypoparathyroidism, and achondroplasia. The corporate develops its drugs utilizing its TransCon know-how, which permits the direct utility of proteins, peptides, and small molecules to focus on areas of the physique by means of a provider drug with recognized organic motion. Along with its main pipeline, Ascendis additionally has two oncology drug candidates in preclinical growth. The corporate’s pediatric development hormone deficiency (GHD) drug, TransCon HGH (lonapegsomatropin), has accomplished a Part 3 trial and the corporate is making ready for the PDUFA date on the finish of June – with expectation of launching the drug commercially on the US market in 3Q21. Ascendis anticipates a European Fee determination on use of lonapegsomatropin throughout 4Q21. There’s an ongoing world Part 3 trial for adults with GHD, with full enrollment anticipated by early subsequent yr, and Ascendis has submitted its medical trial notification to start a Part 3 trial for pediatric sufferers in Japan. Moreover, the corporate is making ready for Part 3 medical trials for TransCon PTH, a remedy for grownup hypoparathyroidism. The corporate anticipates topline ends in 4Q21. As above, the corporate can be continuing with medical trial notification in Japan, for 2Q21. With all of that within the background, Wedbush analyst Liana Moussatos listed ASND as one in every of her prime picks for 2021 “In 2021, we look ahead to 1) TC-hGH/pediatric development hormone deficiency (GHD; lonapegsomatropin) June 25, 2021, PDUFA date; 2) potential TC-hGH/GHD MAA approval in This autumn:21; and three) topline outcomes from the pivotal Part 3 PaTHway for TCPTH in grownup hypoparathyroidism (HP) in This autumn:21. We see these occasions as potential inflection factors for the inventory. We count on 2021 to be a transformative yr for Ascendis in entrance of a number of potential worth creation occasions,” Moussatos famous. In keeping with these feedback, Moussatos charges ASND shares an Outperform (i.e. Purchase), and units a $209 value goal indicating a 60% one-year upside potential. (To look at Moussatos’ monitor file, click on right here) Moussatos is not any outlier on Ascendis; this inventory has 6 current critiques, with 5 to Purchase and 1 to Maintain. The shares are priced at $130.63 and their $191.25 common value goal suggests 46% development within the subsequent 12 months. (See ASND inventory evaluation on TipRanks) AlloVir (ALVR) The subsequent firm on our checklist, AlloVir, is one other cutting-edge biotech agency. AlloVir’s focus is the event of allogenic, off-the-shelf virus-specific T-cell candidates. These are medication particularly designed to forestall or deal with viral infections in immunocompromised sufferers with T-cell deficiencies – and restricted remedy choices. The corporate’s pipeline options 5 candidate brokers for the remedy of twelve ‘devastating’ viruses, together with HHV-6, EBV, PIV, HBV, and even COVID-19. Essentially the most superior drug candidate within the pipeline, ALVR105, additionally referred to as Viralym-M, is present process trials for a spread of functions, together with the remedy of virus-associated hemorrhagic-cystitis, cytomegalovirus (CMV), and adenovirus (AdV). As well as, there are medical research of the drug candidate as a preventative for BKV, CMV, AdV, EBV, HHV-6 and others viral illnesses. The medical trials vary from Part 1b/2 to Part 3. The corporate’s lead candidate, Viralym-M, is in an ongoing Part 3 trial for the remedy of virus-associated hemorrhagic-cystitis. The corporate additionally exams Viralym-M in two proof-of-concept Part 2 trials. These embrace a medical research of the drug candidate as a primary of its type, multi-virus preventative for HSCT recipients and a research of the drug within the remedy of BK viremia in kidney transplant sufferers. These trials are ongoing, and actively recruiting sufferers. Along with ALVR105/Viralym-M, the corporate subsequent two most superior packages are ALVR 109 and ALVR106. ALVR109 has entered Part 1 proof-of-concept medical trial as a remedy for COVID-19. Preclinical knowledge launched in December demonstrated illness particular antiviral exercise. ALVR 106 has had its investigation new drug (IND) utility authorized, and is cleared to provoke medical trials within the remedy of affect, PIV, and respiratory syncytial virus. In his protection of this inventory for Piper Sandler, 5-star analyst Christopher Raymond writes, “[All] essential timelines stay basically on monitor. To us, essentially the most important of these are Part 2 POC knowledge for Viralym-M within the prevention setting for HSCT sufferers and for Part 2 POC knowledge for Viralym-M within the remedy of BK virus in kidney transplant recipients. These two occasions stay on monitor for 2H21. Whereas we don’t mannequin contribution kind ALVR109 (in high-risk sufferers with COVID-19), we word that POC knowledge from that program can be anticipated 2H21.” On the backside line, Raymond says, “[We] proceed to view ALVR as an rising chief in virus particular cell therapies… it stays a prime 2021 decide.” To this finish, Raymond offers ALVR an Obese (i.e. Purchase) score, and his $55 value goal implies a strong upside of ~132% for the yr forward. (To look at Raymond’s monitor file, click on right here) Just like the Piper Sandler analyst, the remainder of the Road is bullish on ALVR. 3 Purchase rankings in comparison with no Holds or Sells add as much as a Sturdy Purchase consensus score. At $49.33, the typical value goal implies upside potential of ~108%. (See ALVR inventory evaluation on TipRanks) Western Digital (WDC) From biotech to high-tech, we’ll change gears and take a look at Western Digital. The corporate produces onerous disks and different knowledge storage, together with SSDs and flash reminiscence. Western Digital’s merchandise are used within the knowledge middle and cloud storage industries; Western Digital contains well-known manufacturers like WD and SanDisk. As will be imagined, Western Digital has seen regular enterprise within the final 18 months, regardless of the COVID pandemic. The transfer towards distant work and digital workplaces put a premium on laptop chips of all types, together with reminiscence and cloud storage. WDC’s revenues have held regular by means of that interval, close to $4 billion quarterly. For the previous two years, the corporate has reported quarterly revenues within the vary between $3.67 billion and $4.29 billion; the newest quarter, 2Q fiscal 21, confirmed $3.94 billion on the prime line, with non-GAAP EPS of 69 cents per share and free money movement of $149 million. The corporate offered ahead steering for fiscal Q3, projecting the highest line between $3.85 billion and $4.05 billion and non-GAAP EPS between 55 and 75 cents. Buyers like predictability, and Western Digital’s efficiency has been simply that. The corporate’s inventory has benefited, and the shares are up 87% over the previous 12 months. It is a modest outperformance in comparison with the NASDAQ index, which is up 73% over the identical interval. C J Muse, 5-star analyst with Evercore ISI, digs deep underneath the hood of Western Digital, and summing up writes, “Whereas WDC shares are up 25% YTD, we see at the very least one other 30% upside fueled by significant constructive revisions to ahead EPS estimates…. consensus estimates are transferring materially greater with potential CY21 exit run fee of ~$10+ (cons $7.60) and extra upside into CY22 (we see stretch objective of $15.00 vs. present cons $7.44)…. With imaginative and prescient to at the very least 30% upside because the NAND business emerges from a cyclical trough, WDC stays a Prime Decide.” Muse places a $100 value goal on WDC, for a 38% one-year upside potential. (To look at Muse’s monitor file, click on right here) Tech firms usually garner numerous analyst consideration, and Western Digital has 21 current inventory critiques. These break all the way down to 17 Buys towards simply 4 Holds, giving the inventory its Sturdy Purchase consensus score. Shares are priced at $72.22, and the $80.26 common goal implies an 11% upside from that stage. (See WDC inventory evaluation on TipRanks) To search out good concepts for shares buying and selling at engaging valuations, go to TipRanks’ Finest Shares to Purchase, a newly launched software that unites all of TipRanks’ fairness insights. Disclaimer: The opinions expressed on this article are solely these of the featured analysts. The content material is meant for use for informational functions solely. It is vitally essential to do your personal evaluation earlier than making any funding.